NASDAQ: BGMSBio Green Med Solution Inc Stock
$1.69+0.24 (+16.55%)
Updated Dec 3, 2025
BGMS Price
$1.69
Fair Value Price
N/A
Market Cap
$8.28M
52 Week Low
$1.16
52 Week High
$213.60
P/E
-0.12x
P/B
1.17x
P/S
116.65x
PEG
N/A
Dividend Yield
N/A
Revenue
$81.00k
Earnings
-$5.44M
Gross Margin
21%
Operating Margin
-5,271.6%
Profit Margin
-8,609.9%
Debt to Equity
0.15
Operating Cash Flow
-$6M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BGMS Overview
A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BGMS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BGMS
Ranked#227 of 483
Ranked#227 of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.96 | A | |
| $337.86 | A | |
| $20.86 | A |
Be the first to know about important BGMS news, forecast changes, insider trades & much more!
BGMS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BGMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BGMS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BGMS is good value based on its book value relative to its share price (1.17x), compared to the US Biotechnology industry average (5.27x)
P/B vs Industry Valuation
BGMS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BGMS due diligence checks available for Premium users.
Valuation
BGMS fair value
Fair Value of BGMS stock based on Discounted Cash Flow (DCF)
Price
$1.69
Fair Value
$0.39
Overvalued by
334.20%
BGMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BGMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
203.58x
Market
46.88x
BGMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
5.27x
BGMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BGMS's financial health
Profit margin
Revenue
$81.0k
Net Income
-$988.0k
Profit Margin
-3,090.1%
BGMS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BGMS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.2M
Liabilities
$1.1M
Debt to equity
0.15
BGMS's short-term assets ($6.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BGMS's short-term assets ($6.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BGMS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BGMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$434.0k
Investing
$0.0
Financing
-$3.0k
BGMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BGMS vs Biotech Stocks
Bio Green Med Solution Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.